Health and Healthcare
Genentech Mixes Top-Line & Bottom-Line Numbers (DNA)
Published:
Last Updated:
Genentech, Inc. (NYSE: DNA) today posted earnings of $0.81 per share and $3.408 billion in revenue. That’s below First Call estimates of $0.88 on $3.36 billion in revenue. For what this is worth, Genentech noted that earnings were affected by items.
The biotech giant has also noted that guidance for 2008 is now $3.40 to$3.45, rather than its prior guidance of $3.40 to $3.50.
Genentech saidtwo drugs posted year-over-year declines rather than just one drug lastquarter. The good news is that the company did beat on its top-linenumbers and its key drugs Avastin and Rituxan were slightly ahead ofplan.
Unfortunately, it only looks like we’ll get merger data in the conference call because it wasn’t noted in depth here. One issue Genentech has noted is that it filed for FDA approval for its Avastin in kidney cancer which has spread.
Shares of Genentech closed down 2.5% at $79.12 today, and shares are actually trading up about $2.00.
Jon C. Ogg
October 14, 2008
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
